What makes HIV vaccines backfire?

Image
IANS New York
Last Updated : Jan 03 2015 | 11:45 AM IST

The very immune cells that HIV vaccines aims to increase may already have been affected by the virus, a reason why AIDS vaccines have backfired in more than one clinical trail, a study says.

The findings show the unique challenges that HIV poses in terms of vaccine development.

"One of the reasons why it has been so difficult to make an AIDS vaccine is that the virus infects the very cells of the immune system that any vaccine is supposed to induce," explained senior author Guido Silvestri from Emory University, Georgia, in the US.

A large part of the HIV/AIDS vaccine effort has been focused on developing vaccines that stimulate antiviral T cells.

T cells come in two main categories, defined by the molecules found on their surfaces. While CD8 is a marker for "killer" cells, CD4 is a marker for "helper" cells.

CD4+ T cells are known to be primary targets for HIV and SIV (simian immunodeficiency virus) infection, while several studies have proposed that CD8+ T cells could be valuable in controlling infection.

In this study, researchers immunised monkeys with five different combinations of vaccines encoding SIV proteins.

SIV infected primates may experience AIDS-like illness in humans.

The monkeys received an initial immunisation followed by two booster shots after 16 and 32 weeks.

But the immunisation regimens did not prevent SIV infection. The monkeys that became infected had higher levels of activated CD4+T cells in rectal biopsies before challenge, Silvestri added.

"This study shows that if a vaccine induces high levels of activated CD4+ T cells in mucosal tissues, any potential protective effect of the vaccine may be hampered," he explained.

The findings were published in the journal Proceedings of the National Academy of Sciences.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 03 2015 | 11:40 AM IST

Next Story